CancerLinQ® Signs Major Health Care System as New Participating Practice

For immediate release
September 6, 2018

Contact
Julianne Lee
571-483-1381
julianne.lee@asco.org

Alexandria, Va. — CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO®), has announced that Stanford Health Care has signed an agreement to participate in the CancerLinQ® platform. Stanford Health Care includes Stanford Cancer Institute which is designated as a Comprehensive Cancer Center by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).

“We are thrilled to have Stanford join CancerLinQ as we continually expand our diverse community of practices share data to help develop insights to help improve the quality of care,” said CancerLinQ LLC CEO Cory Wiegert. “Over the past year, CancerLinQ has focused its efforts to successfully onboarding a number of practices to the platform. We look forward to working with Stanford as they incorporate CancerLinQ into their patient care workflow.”

CancerLinQ® is a powerful database containing growing amounts of real-world cancer information. This national initiative allows cancer providers to improve the quality of care by analyzing cancer patient medical records, uncovering patterns and trends, and measuring their care against that of their peers and recommended guidelines.

Stanford Health Care includes patient care, clinical trials, research programs, and an academic center. Its Stanford Cancer Institute is a collaborative of Stanford Health Care, Stanford University School of Medicine, and Stanford Children's Health.

CancerLinQ® is supported in part through Conquer Cancer®, the ASCO Foundation, whose
generous donors have helped make the system possible. Major supporters include Amgen; Astellas; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cancer Treatment Centers of America®; Chan Soon-Shiong Family Foundation; Genentech BioOncology™; HELSINN; Janssen Oncology; Lilly; Raj Mantena, RPh; Novartis Oncology; Pfizer Oncology; Thomas G. Roberts, Jr., MD, and Susan M. DaSilva; and Susan G. Komen®.

CancerLinQ® and CancerLinQ Discovery® are projects of CancerLinQ LLC. For more information, please visit CancerLinQ.org.

###

**About ASCO:**

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world's leading organization of its kind, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at [www.ASCO.org](http://www.ASCO.org), explore patient education resources at [www.Cancer.Net](http://www.Cancer.Net), and follow us on Facebook, Twitter, LinkedIn, and YouTube.

**About CancerLinQ LLC**

CancerLinQ LLC is a subsidiary of the American Society of Clinical Oncology (ASCO) established for the development and operation of the CancerLinQ™ initiative. CancerLinQ® is a health information technology (HIT) platform aimed at enhancing and improving the understanding and treatment of cancer. To learn more, visit [www.cancerlinq.org](http://www.cancerlinq.org).